Eledon Pharmaceuticals
ELDN
19 hedge funds and large institutions have $16.1M invested in Eledon Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 19 closing their positions.
706% more capital invested
Capital invested by funds: $2M → $16.1M (+$14.1M)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
2.34% more ownership
Funds ownership: 0% → 2.34% (+2.3%)
44% less funds holding
Funds holding: 34 → 19 (-15)
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$14.4M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$231K |
| 3 |
ECM
Element Capital Management
New York
|
+$140K |
| 4 |
Renaissance Technologies
New York
|
+$96.8K |
| 5 |
Goldman Sachs
New York
|
+$63.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$230K |
| 2 |
State Street
Boston,
Massachusetts
|
-$115K |
| 3 |
JP Morgan Chase
New York
|
-$89K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$87K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$70K |
ELDN Hedge Fund Activity: Q2 2017 in Review
19 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2017, worth a combined $16.1M — up 706% from $2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ELDN and 4 opened new positions — a net loss of 15 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $14.4M. The largest seller was BlackRock, cutting an estimated $230K.
- 19 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2017, down from 34 in Q1 2017.
- Funds reported $16.1M of Eledon Pharmaceuticals stock for Q2 2017, up 706% quarter-over-quarter.
- 4 funds opened new Eledon Pharmaceuticals positions in Q2 2017 and 19 closed out, a net change of -15 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2017 was OrbiMed, an estimated $14.4M added.
- The largest Eledon Pharmaceuticals seller in Q2 2017 was BlackRock, an estimated $230K sold.
Based on aggregated 13F filings for Q2 2017.